ResearcherUniversity of AugsburgActive in the last 2 years

Nic G. Reitsam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0070-3158; OpenAlex author ID A5038032832, A5136158486. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.ejca.2026.117035 ↗
The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarci… Co-author DOI 10.1186/s12885-024-12519-9 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Bruno Märkl · 2 shared papers, 2024–2026 · strength 0.46
- Paper The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers ho… DOI 10.1186/s12885-024-12519-9 ↗
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Przemyslaw Grochowski · 2 shared papers, 2024–2026 · strength 0.46
- Paper The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers ho… DOI 10.1186/s12885-024-12519-9 ↗
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Michael Guenther · 1 shared paper, 2026 · strength 0.23
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Anna Silvia Wenning · 1 shared paper, 2026 · strength 0.23
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Steffen Ormanns · 1 shared paper, 2026 · strength 0.23
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Konstantin Bräutigam · 1 shared paper, 2026 · strength 0.23
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Martin Wartenberg · 1 shared paper, 2026 · strength 0.23
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Beat Gloor · 1 shared paper, 2026 · strength 0.23
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Robert Grützmann · 1 shared paper, 2026 · strength 0.23
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗
Christian P. Pilarsky · 1 shared paper, 2026 · strength 0.23
- Paper Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma. DOI 10.1016/j.ejca.2026.117035 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.